Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Mandragora autumnalis ethanolic extract (MAE) is a plant-derived substance under investigation for its potential anticancer properties, specifically against triple-negative breast cancer (MDA-MB-231) cell lines. It has been shown to reduce the viability of these cancer cells in a concentration- and time-dependent manner. The extract's mechanism of action involves inducing oxidative stress, increasing the expression of the tumor suppressor p53, and decreasing the expression of the cellular proliferation marker Ki-67, matrix metalloproteinase-9 (MMP-9) which is implicated in extracellular matrix degradation and metastasis, and the transcription factor STAT-3. Furthermore, MAE influences various cellular processes critical for metastasis, including cell cycle progression, migration, angiogenesis, invasion, aggregation, and adhesion, suggesting its potential as a novel therapeutic agent for triple-negative breast cancer.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on mandragora autumnalis ethanolic extract.